Improving patient safety through more proactive risk management

 

  • Revised good pharmacovigilance practices module on risk management systems released for public consultation

 

London, UK (February 29, 2016) – The European Medicines Agency (EMA) has published today a revision of module V of the good pharmacovigilance practices (GVP) on risk management systems for public consultation until 31 May 2016.


Risk management is a major component of the safety monitoring of medicines. Risk management entails putting in place measures to minimise potential risks and to fill knowledge gaps for medicines (e.g. through post-authorisation data). The goal is to ensure that throughout its lifespan the benefits of a particular medicine exceed the risks by the greatest achievable margin. Marketing authorisation holders are required to present the proposed activities in a risk management plan (RMP) that needs to be approved by the regulators before a medicine can be authorised.

 

GVP module V, released in 2012, advises developers of medicines, marketing authorisation holders and regulators on the design of effective risk management systems and plans. This first major revision is based on the experience gained since the Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) started its operations, which includes the review of risk management plans. It further clarifies the activities a risk management plan should focus on during the life cycle of a product. This will help to ensure that a risk-proportionate planning of activities directs resources to areas where the need for additional information and risk minimisation is greatest. GVP module V highlights principles of risk minimisation and therefore, should be read in conjunction with GVP module XVI which focuses on tools for risk minimisation.

 

Together with the GVP module V, EMA is also consulting stakeholders on an amended RMP template, to be used by medicine developers. The revision of the RMP template is based on the principles described in the updated GVP module V in the view of getting a focussed risk management system and simplifying the way information is submitted to the regulators. The RMP template includes a format for a summary of the RMP to be made public, and this format incorporates improvements following a one-year pilot phase. The RMP summary aims at further streamlining and contextualising the information and to better meet the information needs and expectations of interested stakeholders.

 

Comments on the GVP module V should be provided using this template. The completed comments form should be sent to gvp@ema.europa.eu by 31 May 2016.

 

Comments on the RMP template should be provided using this template. The completed comments form should be sent to rmptemplate@ema.europa.eu by 31 May 2016.

 

After comments have been received from stakeholders during the public consultation, the Agency will publish the final versions of the GVP module V and the RMP template together with an implementation plan. Until this time the current versions of the GVP module V and the RMP template remain applicable.

Werbung

 

GVP modules are a set of guidelines to facilitate and strengthen pharmacovigilance in the EU. They apply to marketing authorisation holders, the Agency and medicines regulatory authorities in EU Member States and aim to improve safety for patients. They cover medicines authorised centrally via the Agency as well as medicines authorised at national level.

 

The release of the GVP modules is a key deliverable of the 2010 pharmacovigilance legislation. Each module was developed by a team of experts from the Agency and from EU Member States.

 

 


European Medicines Agency (EMA), 29.02.2016 (tB).

MEDICAL NEWS

Monoclonal antibody therapy for COVID-19 safe, effective for transplant patients
Having trouble falling asleep predicts cognitive impairment in later life
SARS-CoV-2 detectable — though likely not transmissible — on hospital…
Waking just one hour earlier cuts depression risk by double…
Moving one step closer to personalized anesthesia

SCHMERZ PAINCARE

Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern
Wenn Schmerzen nach einer OP chronisch werden

DIABETES

Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…
Minimalinvasive Geräte warnen ungenügend vor Unterzuckerung
Typ-1-Diabetes und Hashimoto-Thyreoiditis treten häufig gemeinsam auf

ERNÄHRUNG

DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren
Gesundheitliche Auswirkungen des Salzkonsums bleiben unklar: Weder der Nutzen noch…

ONKOLOGIE

Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung
Risikobasiertes Brustkrebs-Screening kosteneffektiv
Krebs – eine unterschätzte finanzielle Herausforderung

MULTIPLE SKLEROSE

Goldstandard für Versorgung bei Multipler Sklerose
Patienteninformationen zu Interferon-beta-Präparaten
Zulassung des S1P Modulators Ponesimod zur Behandlung von erwachsenen Patienten…
Neue S2k-Leitlinie für Diagnostik und Therapie der Multiplen Sklerose
Krankheitsbezogenes Kompetenznetz Multiple Sklerose: Stellungnahme zu SARS CoV 2 Impfdaten…

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung